AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 92 min read$LLY

Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.

Original reporting
rttnews.com
Published Oct 9, 2026, 11:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound — source image
Source · rttnews.com
Decision brief

The 30-second read

$LLYNeutralMed
01

Why it matters

The modest biomarker improvements were disclosed for the first time, prompting a small share price decline as the market weighed the early‑stage nature of the data.

02

Market read

First‑report trial data for a combination therapy; modest market reaction suggests limited immediate trading edge but informs longer‑term positioning in biotech.

03

What to watch

Long‑term safety, regulatory pathway, and competitive landscape could dampen upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Eli Lilly announced exploratory Phase 3b results from the TOGETHER‑PsO study, evaluating Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in patients with psoriasis and obesity/overweight.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

Eli Lilly disclosed new Phase 3b exploratory data showing combined Taltz and Zepbound improves immune and metabolic biomarkers in psoriasis‑obesity patients.

Expected impact

likely modest pressure as investors digest the early‑stage results

Evidence & confidence

First‑report trial data; market reaction was a small decline, indicating limited immediate catalyst.

Market effects

Sector

May spur interest in combination therapies for metabolic‑immune overlap, affecting biotech peers.

Regional

US biotech sector could see slight re‑rating as investors assess early data relevance.

Global

Limited to global pharma investors tracking obesity‑psoriasis treatment pipelines.

Counterpoint

What could challenge this read

Data are early‑stage and may not translate to commercial benefit; caution on over‑optimism.

Key entities

  • Company
    Eli Lilly

    Pharmaceutical company reporting trial data.

  • Drug
    Taltz

    Ixekizumab, a psoriasis treatment.

  • Drug
    Zepbound

    Tirzepatide, a metabolic therapy.

Read at source← All news

StoryEli Lilly presents exploratory biomarker data from TOGETHER‑PsO Phase 3b trial

Also covered by

1 outlet

Related articles

OCT 9
$LLYMedAI 9/10

New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

zmescience.com2 min
OCT 9
$LLYMed

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity | Eli Lilly and Company

Eli Lilly presented Phase 3b data from the TOGETHER-PsO study, showing that Taltz (ixekizumab) and Zepbound (tirzepatide) together led to broader biomarker changes in psoriasis and obesity patients compared to Taltz alone. The combination therapy showed greater reductions in inflammatory immune activity and improved psoriasis-specific markers by Week 12. The study involved 274 participants and evaluated the efficacy and safety of the combination treatment over 52 weeks.

investor.lilly.com3 min
OCT 9
$LLYMed

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker changes in psoriasis and metabolic markers compared to Taltz alone. The study involved 274 adults with psoriasis and obesity, with results presented at the 2026 Fall Clinical Dermatology Conference.

prnewswire.com2 min
OCT 8
$LLYHigh

Hand and Foot Eczema Responds Well to Lebrikizumab

A phase 3b trial of lebrikizumab (Ebglyss) showed over 50% of patients with moderate-to-severe hand and foot eczema achieved clear or almost clear skin. Significant reductions in itch and pain were reported, with 76.7% of patients satisfied with skin clearance. Lebrikizumab, approved for atopic dermatitis, is developed by Eli Lilly and Almirall in Europe.

medscape.com2 min
OCT 8
$LLYMed

Cantor Fitzgerald raises Eli Lilly stock price target on demand trends

Cantor Fitzgerald raised its price target for Eli Lilly (NYSE:LLY) to $1,440, citing strong demand trends and potential tailwinds from new products. The stock trades at $1,189 with a market cap of $1.06 trillion. Analysts note pricing headwinds but highlight a PEG ratio of 0.42 and 49.6% revenue growth. Recent FDA approvals and positive analyst ratings also support the stock.

investing.com2 min